A Phase II Study of Docetaxel in Patients with Metastatic Carcinoid Tumors
Matthew H. Kulke(Moffitt Cancer Center), Charles S. Fuchs(University of Southern California), Robert J. Mayer(Applied Natural Sciences), David P. Ryan(East Carolina University), Keith Stuart(Brigham and Women's Hospital), Haesook Kim(Dana-Farber Cancer Institute), Jeffrey W. Clark(Massachusetts General Hospital), Michele Vincitore(Dana-Farber Cancer Institute)
Cited by 61
Related Papers
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2010|4.5k
Phase 3 Trial of <sup>177</sup> Lu-Dotatate for Midgut Neuroendocrine Tumors
|New England Journal of Medicine|2017|3.2k
Fusobacterium nucleatum Potentiates Intestinal Tumorigenesis and Modulates the Tumor-Immune Microenvironment
|Cell Host & Microbe|2013|2.7k
Crizotinib in <i>ROS1</i>-Rearranged Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2014|2k